Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a open-label preventive study of S6G1T0-01 in adults with high-frequency basal cell carcinoma without Gorlin syndrome
MOH_2026-07-06_016919Phase 2Not yet recruiting
- Sponsor
- Sol-Gel Technologies
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of patidegib in basal cell carcinoma (BCC), sponsored by Sol-Gel Technologies. Primary endpoint: New basal cell carcinoma lesions in the treated area. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
patidegib
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on MOH_2026-07-06_016919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-07-06_016919.